sorafenib has been researched along with triazoles in 14 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (triazoles) | Trials (triazoles) | Recent Studies (post-2010) (triazoles) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 25,808 | 2,252 | 13,501 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 6 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Alfieri, RR; Belletti, S; Bonelli, MA; Bottini, A; Cavazzoni, A; Dowsett, M; Evans, DB; Fox, SB; Fumarola, C; Galetti, M; Gatti, R; Generali, D; Harris, AL; La Monica, S; Martin, LA; Petronini, PG | 1 |
| Chung, GG; Cohen, P; Creswell, K; Eng-Wong, J; Herbolsheimer, P; Isaacs, C; Liu, MC; Novielli, A; Ottaviano, Y; Slack, R; Smith, KL; Warren, R; Wilkinson, M | 1 |
| Gradishar, WJ | 1 |
| Baker, SD; Chaudhry, AS; Finkelstein, D; Gibson, A; Inaba, H; Li, L; Roberts, JL; Rubnitz, JE; Schuetz, EG; Zimmerman, EI | 1 |
| Aguggini, S; Allevi, G; Andreis, D; Bazzola, L; Berruti, A; Bertoni, R; Bottini, A; Ferrozzi, F; Foroni, C; Fox, SB; Gatter, K; Generali, D; Giardini, R; Harris, AL; Martinotti, M; Milani, M; Petronini, PG; R Cappelletti, M; Reynolds, AR; Strina, C; Turley, H; Venturini, S; Zanoni, V | 1 |
| Chen, C; Chen, W; Guo, L; Ju, R; Li, J; Shi, J; Sun, F; Ye, C; Zhang, D; Zhu, L | 1 |
| Gong, P; Qin, M; Yao, Q; Ye, W; Yu, S | 1 |
| Geng, P; Liu, Y; Qin, J; Sun, M; Sun, X; Wu, C; Wu, Y; Yin, Y; Zhan, X; Zhang, S; Zhuang, Z | 1 |
| Abdouni, A; Allende, DS; Apte, SS; Arechederra, M; Audebert, S; Bazai, SK; Daian, F; Dono, R; Gregoire, D; Hibner, U; Lozano, A; Maina, F; Mead, TJ; Richelme, S; Sequera, C | 1 |
| Boonsombat, J; Chuaypen, N; Ketkaew, Y; Limpachayaporn, P; Palakhachane, S; Ruchirawat, S; Sirirak, J; Suksamrarn, A; Tangkijvanich, P | 1 |
| Al-Hossaini, AM; Al-Mehizi, AA; Alanazi, MM; Alkahtani, HM; Alsaif, NA; Elwan, A; Mahdy, HA; Obaidullah, AJ; Taghour, MS | 1 |
| Arafa, RK; Balkan, A; Unsal Tan, O; Zengin, M | 1 |
| Abulkhair, HS; Fayed, EA; Husseiny, EM; Othman, EM | 1 |
| Charoensuksai, P; Chuaypen, N; Limpachayaporn, P; Nuchpun, S; Sirirak, J; Suksamrarn, A; Tangkijvanich, P; Wongprayoon, P | 1 |
1 review(s) available for sorafenib and triazoles
| Article | Year |
|---|---|
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles | 2012 |
2 trial(s) available for sorafenib and triazoles
| Article | Year |
|---|---|
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzenesulfonates; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Sorafenib; Stem Cells; Time Factors; Treatment Outcome; Triazoles; United States | 2011 |
Ontogeny and sorafenib metabolism.
Topics: Adolescent; Age Factors; Azoles; Child; Child, Preschool; Cytochrome P-450 CYP3A; Female; Humans; Infant; Infant, Newborn; Liver; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sex Factors; Sorafenib; Triazoles; Voriconazole; Young Adult | 2012 |
11 other study(ies) available for sorafenib and triazoles
| Article | Year |
|---|---|
Synergistic activity of letrozole and sorafenib on breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Inducing Factor; Aromatase; Aromatase Inhibitors; Benzenesulfonates; Breast Neoplasms; Caspase 7; Caspase 9; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cytochromes c; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Humans; Letrozole; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Niacinamide; Nitriles; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-myc; Pyridines; Retinoblastoma Protein; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Testosterone; Time Factors; TOR Serine-Threonine Kinases; Transfection; Triazoles | 2010 |
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
Topics: Administration, Metronomic; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Female; Humans; Letrozole; Middle Aged; Niacinamide; Nitriles; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Triazoles | 2015 |
Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Synergism; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Nanog Homeobox Protein; Niacinamide; Phenylurea Compounds; Sorafenib; Triazoles; Xenograft Model Antitumor Assays | 2017 |
Synthesis and Antitumor Activity of Triazole-Containing Sorafenib Analogs.
Topics: Antineoplastic Agents; Apoptosis; Catalysis; Cell Proliferation; Cell Survival; Coordination Complexes; Copper; Cycloaddition Reaction; HT29 Cells; Humans; Sorafenib; Structure-Activity Relationship; Triazoles | 2017 |
EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Topics: Animals; Antineoplastic Agents; Azepines; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Mice; Proteins; Proto-Oncogene Proteins c-myc; Signal Transduction; Sorafenib; Triazoles; Xenograft Model Antitumor Assays | 2019 |
ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.
Topics: ADAMTS Proteins; ADAMTS5 Protein; Animals; Antineoplastic Agents, Immunological; Benzocycloheptenes; Carcinogenesis; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epigenomics; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Phenylurea Compounds; Quinolines; Signal Transduction; Sorafenib; Transcriptional Activation; Triazoles; Tumor Microenvironment | 2021 |
Synthesis of sorafenib analogues incorporating a 1,2,3-triazole ring and cytotoxicity towards hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Sorafenib; Structure-Activity Relationship; Triazoles; Wound Healing | 2021 |
Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Computer Simulation; Female; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Mice; Quinoxalines; Rats; Sorafenib; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Design and synthesis of new 2-oxoquinoxalinyl-1,2,4-triazoles as antitumor VEGFR-2 inhibitors.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia.
Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Cell Cycle; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid; Molecular Docking Simulation; Molecular Structure; Semicarbazones; Sorafenib; Structure-Activity Relationship; Thiosemicarbazones; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
meta-Ureidophenoxy-1,2,3-triazole hybrid as a novel scaffold for promising HepG2 hepatocellular carcinoma inhibitors: Synthesis, biological evaluation and molecular docking studies.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Molecular Docking Simulation; Molecular Structure; Sorafenib; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2 | 2022 |